Xoten C 10mg/75mg Capsule is a combination medication containing Rosuvastatin 10mg and Clopidogrel 75mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins, thereby decreasing the risk of atherosclerosis and related cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, preventing thrombus formation. This combination is particularly beneficial in patients with established coronary artery disease, recent myocardial infarction, stroke, or peripheral arterial disease, where dual action on cholesterol management and platelet inhibition is required. Xoten C should be administered under medical supervision, with dosage adjustments based on lipid profiles, platelet function, and patient tolerance. Common adverse effects include gastrointestinal disturbances, myalgia, and increased risk of bleeding. Periodic monitoring of liver function tests, creatine kinase levels, and complete blood counts is recommended to detect potential side effects early. Contraindications include active liver disease, hypersensitivity to components, and conditions predisposing to bleeding. Xoten C 10mg/75mg Capsule offers a synergistic approach to cardiovascular risk reduction through combined lipid-lowering and antithrombotic mechanisms.